Lung Cancer Clinical Trials in New York

Showing 301-320 of 596 trials

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NCT05815186

Study record has been combined with NCT05815173. See NCT05815173 for summary.

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NYU Langone HealthStarted Apr 2024

Garden City, New York, United States • Mineola, New York, United States • New Hyde Park, New York, United States +3 more locations

COMPLETEDPhase 1/2< 1 mile

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NCT03665285

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Advanced or Metastatic Solid TumorsLung CancerBreast Cancer+6 more

NextCure, Inc.109 participantsStarted Oct 2018

Los Angeles, California, United States • New Haven, Connecticut, United States • Hackensack, New Jersey, United States +3 more locations

TERMINATEDPhase 3< 1 mile

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587

The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC who progressed after sequential or concurrent chemotherapy and immune checkpoint inhibitor given in first or second-line treatment. The main questions were to compare the survival, the tolerance to treatment and the quality of life of patients between the two arms of treatment (OSE2101 versus standard chemotherapy)

Non Small Cell Lung Cancer

OSE Immunotherapeutics219 participantsStarted Feb 2016

Burbank, California, United States • Washington D.C., District of Columbia, United States • Boca Raton, Florida, United States +75 more locations

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Lung Cancer Trials in Other Cities

Prospective Clinicogenomic Program

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Risk Communication in African American Smokers

A Study of PRT2527 in Participants With Advanced Solid Tumors

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

The Lung Screening, Tobacco and Health Project

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Lung EpiCheck Biomarkers Development Study

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Survival Prolongation by Rationale Innovative Genomics

International Lung Screen Trial (ILST)

Other Conditions in New York